Arbutus Biopharma Corporation

Pfizer, founded in 1849, is one of the largest research-based pharmaceuticals companies in the United States. The company s areas of expertise include human and animal health, and consumer health care products. Its human health segment offers medicines for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and allergies. The consumer health care segment produces and markets various medications for oral care, upper respiratory and gastrointestinal health, tobacco dependence, skin and eye care, and hair growth. The company s animal health division develops products for the prevention and treatment of diseases in livestock and companion animals. The products offered by the division include parasiticides, anti-inflammatories, vaccines, and antibiotics. The company s well-known brands include Sudafed, Listerine, Benadryl, Lipitor, Diflucan, Zithromax, Viagra and Celebrex. It also produces pharmaceutical chemicals and gelatin capsules, and offers contract-manufacturing services.

Merck, located in Whitehouse Station, NJ, has been dedicated to bringing hope to humanity through the development of crucial medicines and vaccines for over 130 years. The company is committed to following the science where it can make the most significant impact, both now and in the future. Merck's progress is propelled by its clinical trials, which aim to discover new treatments to save and enhance lives. The company tackles tough scientific questions through its trials and collaborations, leading to advancements in healthcare and pharmaceuticals. Generated from the website content

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company based in Berkeley Heights, NJ, focused on developing innovative cancer medicines through the exploration of cell cycle transcriptional regulation, epigenetics, and mitosis biology. The company aims to address oncology and hematology indications by building a diversified pipeline of novel drug candidates that target mechanisms of resistance in cancer cells. As a pioneer in cell cycle biology, Cyclacel is dedicated to reactivating the body's own cell death mechanisms to combat cancer. Currently, the company has two orally available programs in clinical development: Fadraciclib, a CDK2 and CDK9 inhibitor, and Plogosertib, a PLK1 inhibitor. Generated from the website